Acquired by Adaptimmune Therapeutics in June 2023
TCRR - TCR2 Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
TCRR price evolution
TCRR
| (in millions $) | 31 Mar 2023 | 31 Jan 2023 | 29 Oct 2022 | 29 Jul 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.6 | $33.9 | $55.16 | $45.36 |
| Short term investments | $95.86 | $116.43 | $121.98 | $162.03 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $140.49 | $177.62 | $184.08 | $215.83 |
| Long term investments | ||||
| Property, plant & equipment | $9.15 | $28.68 | $86.79 | $90 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.02 | $30.61 | $88.85 | $92.21 |
| Total investments | $95.86 | $116.43 | $121.98 | $162.03 |
| Total assets | $151.51 | $208.24 | $272.93 | $308.04 |
| Current liabilities | ||||
| Accounts payable | $6.32 | $2.79 | $2.96 | $5.47 |
| Deferred revenue | ||||
| Short long term debt | $31.94 | $50.45 | $20.55 | $20.57 |
| Total current liabilities | $47.47 | $64.06 | $36.69 | $38.57 |
| Long term debt | $2.71 | $3.32 | $37.68 | $43.21 |
| Total noncurrent liabilities | $2.71 | $3.32 | $37.68 | $43.21 |
| Total debt | $34.65 | $53.76 | $58.23 | $63.78 |
| Total liabilities | $50.18 | $67.38 | $74.38 | $81.78 |
| Shareholders' equity | ||||
| Retained earnings | -$541.74 | -$501.34 | -$440.84 | -$410.25 |
| Other shareholder equity | -$0.19 | -$0.45 | -$0.6 | -$0.67 |
| Total shareholder equity | $101.33 | $140.86 | $198.55 | $226.26 |
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.9 | $223.72 | $94.74 | $65.71 |
| Short term investments | $116.43 | $43.03 | $133.83 | $92.83 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $177.62 | $276.13 | $235.5 | $163.2 |
| Long term investments | ||||
| Property, plant & equipment | $28.68 | $45.36 | $10 | $4.9 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $30.61 | $47.24 | $10.66 | $5.34 |
| Total investments | $116.43 | $43.03 | $133.83 | $92.83 |
| Total assets | $208.24 | $323.37 | $246.2 | $168.5 |
| Current liabilities | ||||
| Accounts payable | $2.79 | $2.14 | $2.4 | $2.5 |
| Deferred revenue | ||||
| Short long term debt | $50.45 | $3.37 | ||
| Total current liabilities | $64.06 | $18.61 | $8.8 | $7.5 |
| Long term debt | $3.32 | $23 | ||
| Total noncurrent liabilities | $3.32 | $23.29 | $0.81 | $0.55 |
| Total debt | $53.76 | $26.36 | ||
| Total liabilities | $67.38 | $41.89 | $9.6 | $8.1 |
| Shareholders' equity | ||||
| Retained earnings | -$501.34 | -$349.52 | -$249.7 | -$182.6 |
| Other shareholder equity | -$0.45 | -$0.01 | $0.1 | $0.1 |
| Total shareholder equity | $140.86 | $281.48 | $236.55 | $160.45 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $29.27 | $25.2 | $24.79 | $25.77 |
| Selling, general & administrative | $8.2 | $5.8 | $6.31 | $6 |
| Total operating expenses | $41.51 | $61.42 | $31.1 | $31.77 |
| Operating income | -$41.51 | -$61.42 | -$31.1 | -$31.77 |
| Income from continuing operations | ||||
| EBIT | -$40.4 | -$60.41 | -$30.59 | -$31.47 |
| Income tax expense | $0 | $0.1 | $0 | $0.13 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$40.4 | -$60.51 | -$30.59 | -$31.6 |
| Income (for common shares) | -$40.4 | -$60.51 | -$30.59 | -$31.6 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $98.64 | $77.24 | $51.98 | $37.49 |
| Selling, general & administrative | $24.44 | $22.5 | $16.72 | $13.89 |
| Total operating expenses | $153.5 | $99.74 | $68.7 | $51.38 |
| Operating income | -$153.5 | -$99.74 | -$68.7 | -$51.38 |
| Income from continuing operations | ||||
| EBIT | -$151.56 | -$99.52 | -$66.96 | -$47.5 |
| Income tax expense | $0.26 | $0.29 | $0.16 | $0.1 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$151.82 | -$99.81 | -$67.12 | -$47.6 |
| Income (for common shares) | -$151.82 | -$99.81 | -$67.12 | -$97.5 |
| (in millions $) | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 |
|---|---|---|---|---|
| Net income | -$40.4 | -$60.51 | -$30.59 | -$31.6 |
| Operating activities | ||||
| Depreciation | $0.61 | $0.75 | $0.89 | $0.7 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.58 | $2.66 | $2.69 | $2.85 |
| Total cash flows from operations | -$40.01 | -$24.96 | -$25.84 | -$19.53 |
| Investing activities | ||||
| Capital expenditures | $0.39 | -$2.44 | -$4.82 | -$6.21 |
| Investments | $21.3 | $6.1 | $40.38 | -$4.12 |
| Total cash flows from investing | $21.69 | $3.66 | $35.56 | -$10.33 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.11 | $0.03 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.02 | $0.04 | $0.07 | -$0.05 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$18.3 | -$21.26 | $9.79 | -$29.91 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$151.82 | -$99.81 | -$67.12 | -$47.6 |
| Operating activities | ||||
| Depreciation | $3.05 | $2.83 | $1.59 | $0.86 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.38 | $12.27 | $8.49 | $6.7 |
| Total cash flows from operations | -$101.46 | -$81.6 | -$56.74 | -$41.36 |
| Investing activities | ||||
| Capital expenditures | -$15.45 | -$11.45 | -$7.16 | -$3.88 |
| Investments | -$73.03 | $89.9 | -$41.77 | -$16.54 |
| Total cash flows from investing | -$88.49 | $78.45 | -$48.94 | -$20.41 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $132.55 | $134.76 | $79.52 |
| Net borrowings | ||||
| Total cash flows from financing | $0.13 | $132.14 | $134.7 | $79.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$189.82 | $128.98 | $29.02 | $17.75 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 39.24M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$159.92M |
| EBIT | -$162.87M |
| Net Income | -$163.10M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 2.59 |
| Cash/Share | 0.40 |
| EPS | -$4.16 |
|---|---|
| ROA | -69.35% |
| ROE | -97.81% |
| Debt/Equity | 0.48 |
|---|---|
| Net debt/EBITDA | -0.22 |
| Current ratio | 2.96 |
| Quick ratio | 2.96 |